BRAINSTORM CELL THERAPEUTICS INC. (BCLI): Results of Operations and Financial Condition
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2623188d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update NEW YORK, Aug 14, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adu
How this was made
The 30-second read
Why it matters
Traders can update models for cash burn and operating expense trajectory, while also repricing regulatory and operational progress toward the Phase 3b ENDURANCE trial under an FDA SPA.
Market read
Fresh Q2 financials show reduced cash and higher net loss, while the company highlights FDA SPA-backed readiness for a Phase 3b ALS trial, creating a mixed catalyst set.
What to watch
Cash and restricted cash are low versus prior year, while current liabilities and short-term loans remain sizable, increasing sensitivity to additional financings before trial start.
Background
The SEC 8-K (Item 2.02) reports BrainStorm Cell Therapeutics Q2 2026 results and a corporate update focused on NurOwn for ALS and leadership/financing actions.
Ticker impact
BCLI disclosed Q2 2026 financials and said it is completing preparations to initiate the Phase 3b ENDURANCE NurOwn study under an FDA SPA.
Likely modest, two-sided reaction: financing/cash concerns may cap upside, while FDA SPA readiness can support sentiment.
The filing provides fresh balance-sheet and P&L datapoints (cash down, higher G&A, larger net loss) plus a concrete clinical/regulatory readiness update (planned enrollment, SPA with FDA).
Market effects
Adds another data point on how ALS cell-therapy sponsors are using FDA Special Protocol Assessments to de-risk late-stage trial design.
No clear regional spillover beyond US biotech/OTCQB sentiment.
Limited, as the disclosure is US regulatory and company-specific.
Counterpoint
The Phase 3b readiness narrative may not translate into near-term enrollment or cash runway, so dilution risk could dominate the stock reaction.
Key entities
- companyBrainStorm Cell Therapeutics Inc.
OTCQB-listed adult stem cell therapeutics developer; subject of the 8-K with Q2 2026 financials and NurOwn Phase 3b ENDURANCE update.
- programNurOwn (MSC-NTF)
Autologous MSC-derived cell therapy for ALS; company states preparations to initiate Phase 3b ENDURANCE under an FDA Special Protocol Assessment.
- executivePeter J. Pitts
Appointed Executive Chairman and Chief Strategic Regulatory and Policy Officer to lead regulatory, operational, partnership, and capital-markets initiatives.